{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"SCLX","limit":50},"count":50,"signals":[{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":35,"context":"ys in obtaining approval from one or more institutional review boards (IRBs); | | |  |  |  |  IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; | | |  |  |  |  changes to the clinical trial protocol; | | |  |  |  |  delays in recruiting suitable subjects to participate in","filed_date":"2025-12-16","accession":"0001193125-25-319720","full_text":"https://origin.rootz.global/static/filing/0001193125-25-319720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":70,"context":"subject to audit and verification procedures that could result in material changes in the final data. | | |  |  |  |  ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. | | Risks Related to our Business and Operations  |  |  |  |  If we are unable t","filed_date":"2025-12-16","accession":"0001193125-25-319720","full_text":"https://origin.rootz.global/static/filing/0001193125-25-319720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":28,"context":"contained therein, if within 18 months following the closing of the Semnur Acquisition, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Considerati","filed_date":"2025-12-16","accession":"0001193125-25-319720","full_text":"https://origin.rootz.global/static/filing/0001193125-25-319720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ter into such a custodial arrangement prior to or shortly following the consummation of the offering, the development and implementation of our treasury strategy would be delayed, which could cause a material adverse effect on our business, prospects, and market price of our  51 listed securities. If we are not able to enter into a custodial agreement prior to or shortly following the consummation of the offering, we wi","filed_date":"2025-11-14","accession":"0001193125-25-283153","full_text":"https://origin.rootz.global/static/filing/0001193125-25-283153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":18,"context":"following table summarizes the outstanding Eligible Options (i.e., those options granted under the 2022 Plan with an exercise price of $282.80 per share) for the Option Repricing held by our current named executive officers (i.e., Dr. Ji and Mr. Ma), all current executive officers as a group, all current non-employee directors as a group and all other employees, respectively.  |  |  |  |  |  |  |  |  |  | | |  Name |","filed_date":"2025-11-07","accession":"0001193125-25-272322","full_text":"https://origin.rootz.global/static/filing/0001193125-25-272322.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"could have a negative impact on the price of cryptocurrencies we hold and adversely affect our business. The emergence or growth of digital assets other than cryptocurrencies we may hold could have a material adverse effect on our financial condition. There are numerous alternative digital assets and many entities, including consortia and financial institutions, are researching and investing resources into private or pe","filed_date":"2025-09-26","accession":"0001193125-25-220446","full_text":"https://origin.rootz.global/static/filing/0001193125-25-220446.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":43,"context":"Statements; Disclosure Controls and Procedures; Internal Controls Over FinancialReporting; Accountants |  |  |  10 |  | | |  Section 5.7 |  |  Subsidiaries |  |  |  12 |  | | |  Section 5.8 |  |  No Material Adverse Effect or Material Adverse Change |  |  |  12 |  | | |  Section 5.9 |  |  No Undisclosed Liabilities |  |  |  13 |  | | |  Section 5.10 |  |  No Undisclosed Events or Circumstances |  |  |  13 |  | | |  Sec","filed_date":"2025-07-23","accession":"0001193125-25-162938","full_text":"https://origin.rootz.global/static/filing/0001193125-25-162938.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":22,"context":"plurality of the votes cast by the stockholders entitled to vote at such election to be approved. Plurality means that the nominees who receive the largest number of votes cast For such nominees are elected as directors. As a result, only For votes will affect the outcome, and any shares abstained from voting For a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be c","filed_date":"2025-05-16","accession":"0000950170-25-073612","full_text":"https://origin.rootz.global/static/filing/0000950170-25-073612.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":21,"context":"sary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilexs named executive officers in 2024. As an emerging growth company as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure","filed_date":"2025-04-29","accession":"0000950170-25-060302","full_text":"https://origin.rootz.global/static/filing/0000950170-25-060302.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"tributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, ac","filed_date":"2025-03-31","accession":"0000950170-25-047800","full_text":"https://origin.rootz.global/static/filing/0000950170-25-047800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":82,"context":"ailable and are subject to audit and verification procedures that could result in material changes in the final data.  ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  If we are unable to retain our ke","filed_date":"2025-03-31","accession":"0000950170-25-047800","full_text":"https://origin.rootz.global/static/filing/0000950170-25-047800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ented costs of investigation and defense and actual, reasonable and documented attorneys fees and expenses), charge, fine, penalty, obligation, judgment, award, assessment, claim or cause of action.  Material Adverse Effect means a material adverse effect on (a) the legality, validity or enforceability of the Material Contracts, (b) the ability of the Seller Parties to perform their obligations under any of the Transact","filed_date":"2025-03-03","accession":"0001193125-25-043338","full_text":"https://origin.rootz.global/static/filing/0001193125-25-043338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":21,"context":"the obligations under the Existing Notes could cause our stock price to decrease significantly, result in substantial dilution or cause us to be unable to raise additional capital, which could have a material negative effect on our business, financial condition and results of operations. See the risk factor titled We may not have the ability to raise the funds necessary to settle the Oramed Note in cash upon a change of","filed_date":"2025-01-17","accession":"0000950170-25-006755","full_text":"https://origin.rootz.global/static/filing/0000950170-25-006755.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. There is no assurance that we will enter into a definitive agreement with respect to the sale of our wholly owned subsidiary, Semnur, a","filed_date":"2024-08-13","accession":"0000950170-24-096199","full_text":"https://origin.rootz.global/static/filing/0000950170-24-096199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"terms or at all. Risks Related to our Commercial Operations and Product Development  We face potential business disruptions and related risks resulting from the COVID-19 pandemic, which could have a material adverse effect on our business, financial condition and results of operations.  In December 2019, a novel strain of coronavirus, or SARS-CoV-2, was reported to have surfaced in Wuhan, China. SARS-CoV-2 is the virus","filed_date":"2024-05-13","accession":"0000950170-24-058630","full_text":"https://origin.rootz.global/static/filing/0000950170-24-058630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":18,"context":"ication or represented by proxy at the Annual Meeting and entitled to vote thereon to be approved. Plurality means that the nominees who receive the largest number of votes cast For such nominees are elected as directors. As a result, only For votes will affect the outcome, and any shares abstained from voting For a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be c","filed_date":"2024-03-12","accession":"0001193125-24-065969","full_text":"https://origin.rootz.global/static/filing/0001193125-24-065969.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ion of Change, and Patient Global Impression of Change and (iii) evaluation of the safety of a single and repeat SP- 102 injections. Schematic of CLEAR - SP-102 (SEMDEXA) Phase 3 Pivotal Trial 25 Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: For the","filed_date":"2024-03-12","accession":"0000950170-24-029473","full_text":"https://origin.rootz.global/static/filing/0000950170-24-029473.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":80,"context":"ailable and are subject to audit and verification procedures that could result in material changes in the final data.  ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  If we are unable to retain our ke","filed_date":"2024-03-12","accession":"0000950170-24-029473","full_text":"https://origin.rootz.global/static/filing/0000950170-24-029473.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":34,"context":"Note  The Oramed Note issued to Oramed (together with its successors and permitted assigns, the Holder) pursuant to the Scilex-Oramed SPA matures on March21, 2025 and is payable in six principal installments, with the first installment in the principal amount of $5,000,000 payable on December21, 2023, the second installment in the principal amount of $15,000,000 payable on March21, 2024, the next thr","filed_date":"2023-11-20","accession":"0001193125-23-280756","full_text":"https://origin.rootz.global/static/filing/0001193125-23-280756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":55,"context":"subject to audit and verification procedures that could result in material changes in the final data. | | |  |  |  |  ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. | | Risks Related to our Business and Operations  |  |  |  |  If we are unable t","filed_date":"2023-11-20","accession":"0001193125-23-280756","full_text":"https://origin.rootz.global/static/filing/0001193125-23-280756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Considerati","filed_date":"2023-11-20","accession":"0001193125-23-280756","full_text":"https://origin.rootz.global/static/filing/0001193125-23-280756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"Yorkville amended the Convertible Debentures to extend the maturity date of the Convertible Debentures to March 15, 2024 (see Note 13). The outstanding principal amount is to be repaid in equal installments that are due every 30 days beginning on May 20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provide a conver","filed_date":"2023-11-14","accession":"0000950170-23-063810","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063810.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":51,"context":"nd are subject to audit and verification procedures that could result in material changes in the final data.  &#x2022; ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  &#x2022; If we are unable to reta","filed_date":"2023-11-14","accession":"0000950170-23-063810","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063810.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":53,"context":"nd are subject to audit and verification procedures that could result in material changes in the final data.  &#x2022; ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  &#x2022; If we are unable to reta","filed_date":"2023-08-11","accession":"0000950170-23-041842","full_text":"https://origin.rootz.global/static/filing/0000950170-23-041842.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":40,"context":"of the foregoing or the Loans, as the same may be amended, modified or supplemented from time to time; all of which shall be in form and substance acceptable to Lender in its Permitted Discretion.  **Material Adverse Effect**or**Material Adverse Change**shall mean any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation","filed_date":"2023-06-27","accession":"0001193125-23-176273","full_text":"https://origin.rootz.global/static/filing/0001193125-23-176273.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":47,"context":"nd are subject to audit and verification procedures that could result in material changes in the final data.  &#x2022; ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  &#x2022; If we are unable to reta","filed_date":"2023-05-12","accession":"0000950170-23-021743","full_text":"https://origin.rootz.global/static/filing/0000950170-23-021743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2023-05-05","accession":"0001193125-23-137199","full_text":"https://origin.rootz.global/static/filing/0001193125-23-137199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"ment Dates. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.  (2) PAYMENTS  (a) Installment Payments. On or before each date (each, an Installment Date) set forth on the repayment schedule attached as Exhibit I hereto (the Repayment Schedule), the Company shall repay a portion of the out","filed_date":"2023-04-20","accession":"0001193125-23-108354","full_text":"https://origin.rootz.global/static/filing/0001193125-23-108354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"ment Dates. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.  (2) PAYMENTS  (a) Installment Payments. On or before each date (each, an Installment Date) set forth on the repayment schedule attached as Exhibit I hereto (the Repayment Schedule), the Company shall repay a portion of the out","filed_date":"2023-04-11","accession":"0001193125-23-097796","full_text":"https://origin.rootz.global/static/filing/0001193125-23-097796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ication or represented by proxy at the Annual Meeting and entitled to vote thereon to be approved. Plurality means that the nominees who receive the largest number of votes cast For such nominees are elected as directors. As a result, only For votes will affect the outcome, and any shares abstained from voting For a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be c","filed_date":"2023-03-08","accession":"0001193125-23-064537","full_text":"https://origin.rootz.global/static/filing/0001193125-23-064537.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":49,"context":"ble and are subject to audit and verification procedures that could result in material changes in the final data.  70 &#x2022; ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.  Risks Related to our Business and Operations  &#x2022; If we are unable to reta","filed_date":"2023-03-07","accession":"0000950170-23-006493","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"n the preamble of this Agreement. Investor Indemnitees shall have the meaning set forth in Section 5.01.  Market Price shall mean VWAP of the Common Shares during the relevant Pricing Period.  - 2 -  Material Adverse Effect shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the t","filed_date":"2023-02-09","accession":"0001193125-23-030002","full_text":"https://origin.rootz.global/static/filing/0001193125-23-030002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of  15  Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2023-01-17","accession":"0001193125-23-009256","full_text":"https://origin.rootz.global/static/filing/0001193125-23-009256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"applicable Advance Notice for such Advance, as the case may be.  Market Price shall mean the VWAP of the Common Shares during the relevant Pricing Period or Additional Pricing Period, as applicable.  Material Adverse Effect shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the t","filed_date":"2023-01-09","accession":"0001193125-23-004041","full_text":"https://origin.rootz.global/static/filing/0001193125-23-004041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"the meaning set forth in Section 5.01.  Market Price shall mean the lowest daily VWAP of the Common Shares during the relevant Pricing Period, other than the daily VWAP on any Excluded Days.  - 2 -  Material Adverse Effect shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the t","filed_date":"2022-11-18","accession":"0001193125-22-287974","full_text":"https://origin.rootz.global/static/filing/0001193125-22-287974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ng a business combination with only a single entity, our lack of diversification may: |  |  |  subject us to numerous economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to a business combination, and | | |  |  |  | | |  |  |  result in our dependency upon the performance of a single operating business o","filed_date":"2022-02-24","accession":"0001213900-22-009229","full_text":"https://origin.rootz.global/static/filing/0001213900-22-009229.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ng a business combination with only a single entity, our lack of diversification may: |  |  |  subject us to numerous economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to a business combination, and | | |  |  |  | | |  |  |  result in our dependency upon the performance of a single operating business o","filed_date":"2021-03-31","accession":"0001213900-21-019230","full_text":"https://origin.rootz.global/static/filing/0001213900-21-019230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"tible promissory note from Denali |  |  |  |  |  |  (48 |  ) |  | |  Net cash used for investing activities |  |  (709 |  ) |  |  |  (548 |  ) |  | |  Financing activities |  |  |  |  |  |  | |  Installment payment of Tranche B Note |  |  (6,319 |  ) |  |  |  (8,874 |  ) |  | |  Payments on purchased revenue liability |  |  (1,192 |  ) |  |  |  (1,156 |  ) |  | |  Payments of Vivasor debt |  |  (2,47","filed_date":"2026-08-14","accession":"0001193125-26-352464","full_text":"https://origin.rootz.global/static/filing/0001193125-26-352464.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"lower than $0.50 per share. The maturity date of the Convertible Debentures was also extended from December 21, 2023 to March 15, 2024. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May 20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conve","filed_date":"2024-08-13","accession":"0000950170-24-096199","full_text":"https://origin.rootz.global/static/filing/0000950170-24-096199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":88,"match_count":1,"context":"or 86% and 85% of the Companys revenue for the years ended December31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December31, 2024 and 2023, three customers represented 95% and 91% of the Companys outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December31","filed_date":"2025-12-16","accession":"0001193125-25-319720","full_text":"https://origin.rootz.global/static/filing/0001193125-25-319720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ramed SPA), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9 million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0 million payable on December 21, 2023, the second installment in the principal amount of $15.0 million payable on March 21, 2024, the next three installments ea","filed_date":"2025-11-14","accession":"0001193125-25-283153","full_text":"https://origin.rootz.global/static/filing/0001193125-25-283153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"lower than $0.50 per share. The maturity date of the Convertible Debentures was also extended from December 21, 2023 to March 15, 2024. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May 20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conve","filed_date":"2024-05-13","accession":"0000950170-24-058630","full_text":"https://origin.rootz.global/static/filing/0000950170-24-058630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"pain population represents a commercially attractive strategy. We intend initially to evaluate SP-103 in a Phase 2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, two-period cross-over, multicenter study of SP-103 and placebo in subjects with acute LBP. The study consists of a 7-day open-label run-in period where all subjects rece","filed_date":"2023-03-07","accession":"0000950170-23-006493","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_concentration","strength":68,"match_count":1,"context":"86% and 85% of the Companys revenue for the years ended December 31, 2024 and 2023, respectively, individually ranging from 23% to 34% and 22% to 32%, respectively. As of December 31, 2024 and 2023, three customers represented 95% and 91% of the Companys outstanding accounts receivable, respectively, individually ranging between 30% and 33% and 24% and 36% for respective periods. Additionally, during the years ended December 3","filed_date":"2025-03-31","accession":"0000950170-25-047800","full_text":"https://origin.rootz.global/static/filing/0000950170-25-047800.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ramed SPA), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9 million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0 million payable on December 21, 2023, the second installment in the principal amount of $15.0 million payable on March 21, 2024, the next three installments ea","filed_date":"2025-08-13","accession":"0000950170-25-108029","full_text":"https://origin.rootz.global/static/filing/0000950170-25-108029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":63,"match_count":6,"context":"tes could result in an event of default. The events of default under the Oramed Note include, among others, a change of control of our company and under the Tranche B Notes include, among others, any material adverse effect on our business, properties, assets, liabilities, operation, condition or prospects. Upon an event of default under the Oramed Note or the Tranche B Notes, subject to notice requirements in the case","filed_date":"2025-08-13","accession":"0000950170-25-108029","full_text":"https://origin.rootz.global/static/filing/0000950170-25-108029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"lower than $0.50 per share. The maturity date of the Convertible Debentures was also extended from December 21, 2023 to March 15, 2024. The outstanding principal amount was to be repaid in equal installments that are due every 30 days beginning on May 20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provided a conve","filed_date":"2025-01-17","accession":"0000950170-25-006755","full_text":"https://origin.rootz.global/static/filing/0000950170-25-006755.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":55,"match_count":5,"context":"ional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. There is no assurance that we will complete the Business Combination with respect to the sale of our wholly owned subsidiary, Semnur, a","filed_date":"2025-05-14","accession":"0000950170-25-071517","full_text":"https://origin.rootz.global/static/filing/0000950170-25-071517.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":53,"match_count":6,"context":"ions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Considerati","filed_date":"2023-03-07","accession":"0000950170-23-006493","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SCLX","company":"Scilex Holding Co","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ramed SPA), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9 million, was to mature on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0 million payable on December 21, 2023, the second installment in the principal amount of $15.0 million payable on March 21, 2024, the next three installments ea","filed_date":"2025-05-14","accession":"0000950170-25-071517","full_text":"https://origin.rootz.global/static/filing/0000950170-25-071517.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"2351106c6eef5d996fc43716ef186298ec304fc96611c1787e2850afdad81628","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7e6d013692eea21fa28c601b66e3738dd6b8fdd9c7ab4417ecf8e6470bcac6fb","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":460,"hourly_limit":500,"remaining":40,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}